CRVS
Price
$4.21
Change
+$0.09 (+2.18%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
324.65M
47 days until earnings call
VKTX
Price
$28.18
Change
+$1.09 (+4.02%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
3.16B
26 days until earnings call
Interact to see
Advertisement

CRVS vs VKTX

Header iconCRVS vs VKTX Comparison
Open Charts CRVS vs VKTXBanner chart's image
Corvus Pharmaceuticals
Price$4.21
Change+$0.09 (+2.18%)
Volume$29.77K
Capitalization324.65M
Viking Therapeutics
Price$28.18
Change+$1.09 (+4.02%)
Volume$84.06K
Capitalization3.16B
CRVS vs VKTX Comparison Chart in %
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. VKTX commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Buy and VKTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (CRVS: $4.21 vs. VKTX: $28.17)
Brand notoriety: CRVS and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 76% vs. VKTX: 152%
Market capitalization -- CRVS: $324.65M vs. VKTX: $3.16B
CRVS [@Biotechnology] is valued at $324.65M. VKTX’s [@Biotechnology] market capitalization is $3.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRVS and VKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 5 bearish.
  • VKTX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than VKTX.

Price Growth

CRVS (@Biotechnology) experienced а +7.12% price change this week, while VKTX (@Biotechnology) price change was +7.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

VKTX is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($3.16B) has a higher market cap than CRVS($325M). CRVS YTD gains are higher at: -21.308 vs. VKTX (-29.995). CRVS has higher annual earnings (EBITDA): -31.13M vs. VKTX (-171.93M). VKTX has more cash in the bank: 852M vs. CRVS (44.2M). VKTX has less debt than CRVS: VKTX (1M) vs CRVS (1.15M). CRVS (0) and VKTX (0) have equivalent revenues.
CRVSVKTXCRVS / VKTX
Capitalization325M3.16B10%
EBITDA-31.13M-171.93M18%
Gain YTD-21.308-29.99571%
P/E RatioN/AN/A-
Revenue00-
Total Cash44.2M852M5%
Total Debt1.15M1M115%
FUNDAMENTALS RATINGS
CRVS vs VKTX: Fundamental Ratings
CRVS
VKTX
OUTLOOK RATING
1..100
7761
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
8976
SMR RATING
1..100
9891
PRICE GROWTH RATING
1..100
3764
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (41) in the Biotechnology industry is in the same range as CRVS (66) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as CRVS (89) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's SMR Rating (91) in the Biotechnology industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as VKTX (64) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VKTX’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as VKTX (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BKMC101.951.30
+1.30%
BNY Mellon US Mid Cap Core Equity ETF
FXR73.780.93
+1.28%
First Trust Indtls/PrdcrDurbAlphaDEX®ETF
CFIZX14.05N/A
N/A
Columbia Flexible Capital Income Inst
ACWEX16.01N/A
N/A
Cavanal Hill World Energy C
GSRRX11.22N/A
N/A
Goldman Sachs Rising Dividend Gr R

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+2.18%
SYRE - CRVS
39%
Loosely correlated
+3.96%
VKTX - CRVS
35%
Loosely correlated
+3.99%
TERN - CRVS
35%
Loosely correlated
-1.48%
IPSC - CRVS
34%
Loosely correlated
+0.23%
FULC - CRVS
34%
Loosely correlated
+3.07%
More

VKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with GPCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VKTX
1D Price
Change %
VKTX100%
+3.99%
GPCR - VKTX
50%
Loosely correlated
-3.26%
CRNX - VKTX
48%
Loosely correlated
-1.38%
KRYS - VKTX
47%
Loosely correlated
+0.06%
ALT - VKTX
47%
Loosely correlated
-53.18%
ROIV - VKTX
45%
Loosely correlated
+1.75%
More